Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS in pancreatic cancer: new drugs on the horizon
Sahar F. Bannoura, Md. Hafiz Uddin, Misako Nagasaka, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 819-835
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, et al.
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 1102-1120
Open Access | Times Cited: 33
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Misako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102309-102309
Open Access | Times Cited: 56
Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment
Mubin Tarannum, Juan L. Vivero‐Escoto
Advanced Drug Delivery Reviews (2022) Vol. 187, pp. 114357-114357
Open Access | Times Cited: 40
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zining Zhang, Heng Zhang, Xiang Liao, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 28
A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance
Jing Zhou, Nan Lyu, Qiongling Wang, et al.
Cancer Letters (2023) Vol. 578, pp. 216457-216457
Open Access | Times Cited: 27
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Jinming Liu, Biao Zhang, Bingqian Huang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Lipid nanomaterials-based RNA therapy and cancer treatment
Xingcai Zhang, Luo Hai, Yibo Gao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 3, pp. 903-915
Open Access | Times Cited: 33
Drug Delivery Strategies for the Treatment of Pancreatic Cancer
Oluwabukunmi Olajubutu, Omotola D. Ogundipe, Amusa S. Adebayo, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1318-1318
Open Access | Times Cited: 17
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Koushik Mondal, Mahesh Kumar Posa, Revathi P Shenoy, et al.
Cells (2024) Vol. 13, Iss. 14, pp. 1221-1221
Open Access | Times Cited: 6
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Predictive biomarkers of pancreatic cancer metastasis: A comprehensive review
Mengting Chen, Hongsen Liu, Yufei Xiao, et al.
Clinica Chimica Acta (2025), pp. 120176-120176
Closed Access
Advancing Targeted Therapies in Pancreatic Cancer: Leveraging Molecular Aberrations for Therapeutic Success
Tanvi Gupta, Mohd Murtaza
Progress in Biophysics and Molecular Biology (2025)
Closed Access
Construction of T-Cell-Related Prognostic Risk Models and Prediction of Tumor Immune Microenvironment Regulation in Pancreatic Adenocarcinoma via Integrated Analysis of Single-Cell RNA-Seq and Bulk RNA-Seq
Dingya Sun, Yijie Hu, Jun Peng, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2384-2384
Open Access
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
Sajid Khan, Vivekananda Budamagunta, Daohong Zhou
Advances in cancer research (2023), pp. 145-184
Closed Access | Times Cited: 11
Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD)
Yuhan Yang, Lei Cao, Zengya Guo, et al.
Experimental Cell Research (2022) Vol. 421, Iss. 2, pp. 113402-113402
Closed Access | Times Cited: 16
New Treatment Options in Metastatic Pancreatic Cancer
Marta Fudalej, Daria Kwaśniewska, Paweł Nurzyński, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2327-2327
Open Access | Times Cited: 9
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
Enrico Gurreri, Giannicola Genovese, Luigi Perelli, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9313-9313
Open Access | Times Cited: 9
Pharmacokinetics, Bioavailability, and Tissue Distribution of the Kirsten Rat Sarcoma Inhibitor Adagrasib in Rats Using UPLC-MS/MS
Lei Pan, Wanying Shen, Huijuan Tang, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 1-12
Open Access | Times Cited: 3
An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review
Ahmed Sabt, Haytham O. Tawfik, Eman F. Khaleel, et al.
Molecular Diversity (2024)
Closed Access | Times Cited: 3
Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives
Belén Toledo, Chiara Deiana, Fabio Scianò, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 323-347
Open Access | Times Cited: 3
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
Robert J. Norgard, Pratha Budhani, Sarah A. O’Brien, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 6, pp. 1548-1560
Open Access | Times Cited: 3
High‐yield nanovesicles extruded from dental follicle stem cells promote the regeneration of periodontal tissues as an alternative of exosomes
Lu Liang, Limeiting Wang, Zhenhui Liao, et al.
Journal Of Clinical Periodontology (2024) Vol. 51, Iss. 10, pp. 1395-1407
Closed Access | Times Cited: 3
Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
Shaila A. Shetu, Debasish Bandyopadhyay
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3706-3706
Open Access | Times Cited: 14
A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma
Hui Tang, Yuping Ge, Tingting You, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top